175 related articles for article (PubMed ID: 30692213)
1. The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.
Chellappa S; Kushekhar K; Munthe LA; Tjønnfjord GE; Aandahl EM; Okkenhaug K; Taskén K
J Immunol; 2019 Mar; 202(5):1397-1405. PubMed ID: 30692213
[TBL] [Abstract][Full Text] [Related]
2. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
Krause G; Hassenrück F; Hallek M
Drug Des Devel Ther; 2018; 12():2577-2590. PubMed ID: 30174412
[TBL] [Abstract][Full Text] [Related]
3. Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.
Lim EL; Cugliandolo FM; Rosner DR; Gyori D; Roychoudhuri R; Okkenhaug K
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875319
[TBL] [Abstract][Full Text] [Related]
4. Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia.
Gadi D; Griffith A; Wang Z; Tyekucheva S; Rai V; Fernandes SM; Machado JH; Munugalavadla V; Lederer J; Brown JR
Br J Haematol; 2022 Apr; 197(2):207-211. PubMed ID: 35170759
[TBL] [Abstract][Full Text] [Related]
5. Idelalisib activates AKT via increased recruitment of PI3Kδ/PI3Kβ to BCR signalosome while reducing PDK1 in post-therapy CLL cells.
Mamidi MK; Mahmud H; Maiti GP; Mendez MT; Fernandes SM; Vesely SK; Holter-Chakrabarty J; Brown JR; Ghosh AK
Leukemia; 2022 Jul; 36(7):1806-1817. PubMed ID: 35568768
[TBL] [Abstract][Full Text] [Related]
6. Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia.
Yin Y; Athanasiadis P; Karlsen L; Urban A; Xu H; Murali I; Fernandes SM; Arribas AJ; Hilli AK; Taskén K; Bertoni F; Mato AR; Normant E; Brown JR; Tjønnfjord GE; Aittokallio T; Skånland SS
Clin Cancer Res; 2022 Oct; 28(20):4444-4455. PubMed ID: 35998013
[TBL] [Abstract][Full Text] [Related]
7. The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
Palazzo A; Herter S; Grosmaire L; Jones R; Frey CR; Limani F; Bacac M; Umana P; Oldham RJ; Marshall MJE; Cox KL; Turaj AH; Cragg MS; Klein C; Carter MJ; Tannheimer S
J Immunol; 2018 Apr; 200(7):2304-2312. PubMed ID: 29453281
[TBL] [Abstract][Full Text] [Related]
8. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
Burke RT; Meadows S; Loriaux MM; Currie KS; Mitchell SA; Maciejewski P; Clarke AS; Dipaolo JA; Druker BJ; Lannutti BJ; Spurgeon SE
Oncotarget; 2014 Feb; 5(4):908-15. PubMed ID: 24659719
[TBL] [Abstract][Full Text] [Related]
9. Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.
Pleyer C; Wiestner A; Sun C
Leuk Lymphoma; 2018 Dec; 59(12):2792-2800. PubMed ID: 29764250
[TBL] [Abstract][Full Text] [Related]
10. Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.
Okkenhaug K; Graupera M; Vanhaesebroeck B
Cancer Discov; 2016 Oct; 6(10):1090-1105. PubMed ID: 27655435
[TBL] [Abstract][Full Text] [Related]
11. Loss of Phosphatidylinositol 3-Kinase Activity in Regulatory T Cells Leads to Neuronal Inflammation.
Stark AK; Davenport ECM; Patton DT; Scudamore CL; Vanhaesebroeck B; Veldhoen M; Garden OA; Okkenhaug K
J Immunol; 2020 Jul; 205(1):78-89. PubMed ID: 32414808
[TBL] [Abstract][Full Text] [Related]
12. Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia.
Witkowska M; Majchrzak A; Robak P; Wolska-Washer A; Robak T
Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):617-633. PubMed ID: 37714711
[TBL] [Abstract][Full Text] [Related]
13. Idelalisib for the treatment of non-Hodgkin lymphoma.
Graf SA; Gopal AK
Expert Opin Pharmacother; 2016; 17(2):265-74. PubMed ID: 26818003
[TBL] [Abstract][Full Text] [Related]
14. PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.
Funk CR; Wang S; Chen KZ; Waller A; Sharma A; Edgar CL; Gupta VA; Chandrakasan S; Zoine JT; Fedanov A; Raikar SS; Koff JL; Flowers CR; Coma S; Pachter JA; Ravindranathan S; Spencer HT; Shanmugam M; Waller EK
Blood; 2022 Jan; 139(4):523-537. PubMed ID: 35084470
[TBL] [Abstract][Full Text] [Related]
15. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.
Cuneo A; Barosi G; Danesi R; Fagiuoli S; Ghia P; Marzano A; Montillo M; Poletti V; Viale P; Zinzani PL
Hematol Oncol; 2019 Feb; 37(1):3-14. PubMed ID: 30187496
[TBL] [Abstract][Full Text] [Related]
16. Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients.
Mattsson A; Sylvan SE; Axelsson P; Ellin F; Kjellander C; Larsson K; Lauri B; Lewerin C; Scharenberg C; Tätting L; Johansson H; Österborg A; Hansson L
Eur J Haematol; 2023 Nov; 111(5):715-721. PubMed ID: 37501508
[TBL] [Abstract][Full Text] [Related]
17. Idelalisib in the management of lymphoma.
Cheah CY; Fowler NH
Blood; 2016 Jul; 128(3):331-6. PubMed ID: 27252232
[TBL] [Abstract][Full Text] [Related]
18. PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives.
Hus I; Puła B; Robak T
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326722
[TBL] [Abstract][Full Text] [Related]
19. PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?
Skånland SS; Brown JR
Haematologica; 2023 Jan; 108(1):9-21. PubMed ID: 35899388
[TBL] [Abstract][Full Text] [Related]
20. Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors.
Gadi D; Martindale SP; Chiu PY; Khalsa J; Chen PH; Fernandes SM; Wang Z; Tyekucheva S; Machado JH; Fisher DC; Armand P; Davids MS; Rodig S; Sherry B; Brown JR
Blood Cancer J; 2023 Feb; 13(1):22. PubMed ID: 36732326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
